TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Phase I Safety Trial of Streptococcus Pneumoniae Whole Cell Vaccine (SPWCV) + Alum in Healthy Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria, Healthy adults:~* If female, not breastfeeding, not pregnant, not planning pregnancy during study period), and willing to consistently use an adequate method of contraception and have repeated pregnancy tests.~* In good health with normal laboratory results~* Willing to comply with study restrictions, study schedule, and can be reliably contacted~Exclusion Criteria:~* Currently consumes alcohol in excess of 2 drinks per day for men or 1 drink per day for women.~* current use or likely requirement for medications with potential for liver injury or effect immune system~* History of event or condition such as anaphylaxis, severe allergic reactions, serious reactions to any vaccines, or other events that might increase risk of reaction to an investigational disease~* History of diabetes, cancer, autoimmune or immunosuppressive disease or chronic such as HIV, Hepatitis B or C

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 40 Years
- Healthy Volunteers: t

Study Arms:
- Cohort 1 SPWCV+Alum 100 mcg (Type: EXPERIMENTAL): each individual receiving 3 vaccinations of same dose 28 days apart
- Cohort 2 SPWCV+Alum 300 mcg (Type: EXPERIMENTAL): each individual receiving 3 vaccinations of same dose 28 days apart
- Cohort 3 SPWCV+Alum 600 mcg (Type: EXPERIMENTAL): each individual receiving 3 vaccinations of same dose 28 days apart
- Normal Saline Injection (Type: PLACEBO_COMPARATOR): placebo group within each cohort receive 3 injections of normal saline 28 days apart~normal saline injection: 3 cohorts of normal saline injection

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Xalacom And Combination Of Unfixed Latanoprost And Timolol In Subjects With Open-Angle Glaucoma Or Ocular Hypertension

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* patients with open-angle glaucoma or ocular hypertension~Exclusion Criteria:~* closed/barely open anterior chamber angle or a history of acute angel closure glaucoma~* Ocular surgery within 3 months

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Furoscix Real-World Evaluation for Decreasing Hospital Admissions in Heart Failure

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age 18-80 years~2. NYHA Class II-III HF presenting to the emergency department for worsening HF at baseline~3. On background therapy includes those receiving 40-160 mg of oral furosemide equivalents daily (20-80 mg Torsemide or 1-4 mg Bumetanide).~4. Signs of extracellular volume expansion, defined as one or more of the following:~   1. jugular venous distention~  2. pitting edema (≥1+),~  3. abdominal distension~  4. pulmonary congestion on chest x-ray~  5. pulmonary rales~5. After initial emergency department evaluation and treatment (i.e., at the time of the care transition decision\*), candidates for parenteral diuresis outside of the hospital, defined as all the following:~   1. Oxygen saturation ≥ 90% on exertion~  2. Respiratory Rate \< 24 breaths per minute~  3. Resting Heart Rate \< 100 beats per minute~  4. Systolic Blood Pressure \> 100 mmHg~6. Adequate environment for at-home administration of Furoscix~Exclusion Criteria:~1. Presence of a complicating condition, other than HF that requires immediate hospitalization or anticipated hospitalization in the next 30 days~2. Evidence of acute renal failure as determined at the discretion of the investigator~3. Known allergy to the active and inactive ingredients of the study medication or device adhesive~4. Any local abdominal skin condition on the day of treatment i.e. sunburn, rash, eczema, etc.~5. Currently participating in another interventional research study~6. Women who are pregnant or who could become pregnant and are not willing to use an adequate form of contraception~7. Estimated Creatinine Clearance \< 30 mL per minute by Cockcroft-Gault equation~   CrCl (mL/min) = {(140 - age) x Lean Body Weight (kg)/Serum Creatinine (mg/dL) x 72} (x 0.85 if female)~8. If baseline creatinine value is available: an increase of ≥ 0.5 mg/dL in creatinine from baseline~9. HF requiring immediate hospitalization

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Furoscix Infusor Prospective Treatment (Type: EXPERIMENTAL): Furoscix (furosemide injection, 8 mg/mL) administered subcutaneously over 5 hours via the Furoscix Infusor outside the hospital.
- Propensity-Matched Historical Control (Type: NO_INTERVENTION): The control arm will be populated with claims data for patients with HF and fluid overload who presented to the emergency department and were admitted to the hospital for ≤ 72 hours for the treatment of HF with intravenous diuretics. Patients admitted for diuresis-only will be identified by using diagnostic codes for admittance from a claims database.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Vaccine Therapy With or Without Imiquimod in Treating Patients With Grade 3 Cervical Intraepithelial Neoplasia

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Colposcopically and biopsy confirmed grade 3 cervical intraepithelial neoplasia~  * Human papillomavirus (HPV) 16-positive disease by PCR~* Measurable disease after diagnostic biopsy~* No concurrent adenocarcinoma in situ of the cervix~PATIENT CHARACTERISTICS:~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use an effective form of contraception during study treatment~* Immunocompetent~* No concurrent malignancy, except for nonmelanoma skin lesions~* No serious concurrent disorder, including any of the following:~  * Active systemic infection~ * Autoimmune disease~ * Proven or suspected immunosuppressive disorder~ * Major medical illnesses of the cardiovascular or respiratory system~* No evidence or history of cardiac disease, including any of the following:~  * Congestive heart failure~ * Symptomatic arrhythmia not controlled by medication~ * Unstable angina~ * History of acute myocardial infarction or cerebrovascular accident within the past 6 months~* No history of severe allergy including eczema or other exfoliative skin disorder~* No active eczema within the past 12 months~* No concurrent skin conditions, including any of the following:~  * Burns~ * Traumatic or pruritic skin conditions~ * Open wounds~ * Unhealed surgical scars~* Patients and their close social, sexual, or domestic contacts may not have any of the following active skin diseases:~  * Psoriasis~ * Lichen planus~ * Sever acneiform rash~ * Impetigo~ * Varicella zoster~ * Sepsis~* No close social contact with children under 5 years old~* No close social or domestic contact with a pregnant woman~* No HIV seropositivity~* No allergy to eggs~PRIOR CONCURRENT THERAPY:~* No previous vaccination with vaccinia~* No immunosuppressive medication (i.e., steroid therapy or other immunosuppressive/immunomodulating drugs \[e.g., cyclosporine\]) within the past 2 months~* No investigational agent(s) within the past 6 months~* No concurrent participation in another experimental protocol

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Groups 1-3 (Type: EXPERIMENTAL): Patients receive pNGVL4a-Sig/E7(detox)/HSP70 DNA vaccine intramuscularly (IM) on days 1 and 29 and TA-HPV vaccine IM on day 57.
- Group 4 (Type: EXPERIMENTAL): Patients receive topical imiquimod on days 1, 29, and 57.
- Group 5 (Type: EXPERIMENTAL): Patients receive pNGVL4a-Sig/E7(detox)/HSP70 DNA vaccine and TA-HPV vaccine as in groups 1-3, and imiquimod as in group 4.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Coversin in Paroxysmal Nocturnal Haemoglobinuria (PNH)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with known Paroxysmal Nocturnal Haemoglobinuria (PNH)~* LDH \>=1.5 Upper Limit of Normal (ULN)~* Resistance to Eculizumab proven by both a recognised C5 polymorphism on genetic screening and complement inhibition on CH50 ELISA of \<100% at concentrations of Eculizumab in excess of 50 μg/mL~* Willing to self-inject Coversin daily or to receive daily subcutaneous injections by a home nurse or in a doctor's office or hospital clinic~* Males or females taking adequate contraceptive precautions if of childbearing potential, 18 - 80 years of age~* Body weight ≥50kg and ≤ 100kg~* The patient has provided written informed consent.~* Willing to avoid prohibited medications for duration of study~* Must agree to take appropriate prophylactic precautions against Neisseria infection.~* Must be counselled regarding the possible reproductive risks of using Coversin and be advised to use an adequate method of contraception pending further data on reproductive toxicology.~Exclusion Criteria:~* Body weight \<50kg or\>100kg~* Pregnancy (females)~* Failure to satisfy the PI of fitness to participate for any other reason~* Known allergy to ticks or severe reaction to arthropod venom (e.g., bee or wasp venom)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Coversin (Nomacopan) (Type: OTHER): This is an open label, non-comparator study.~Patient will be given a single ablating dose of 0.57mg/kg per subject followed by daily repeat maintenance doses. The initial repeat dose will be 25% of the ablating dose. If this is insufficient to maintain complement inhibition at ≤10% of baseline (pre-treatment) level after 5 days of treatment the daily dose will be increased by doubling until that level of inhibition is achieved. In the event of 100% inhibition being achieved the dose may be titrated downwards at the PI's discretion until a satisfactory clinical result is obtained. If at any point in treatment complement inhibition falls to less than 50% of baseline a further ablating dose of 0.57mg/kg should be given. Coversin lyophilised powder in each vial was diluted with 0.6 mL water for injection prior to use.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Primary and Secondary Prevention of Postpartum Hemorrhage at the Community Level in Egypt

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Willing and able to give informed consent~* Vaginal delivery~* Agrees to participate in follow-up interview~* Agrees to have pre- and post-hemoglobin taken~* Delivery at woman's home or at the primary health unit (PHU)~Exclusion Criteria:~* Too advanced into active labor to provide consent~* Known allergy to misoprostol and/or other prostaglandin~* Pregnancy complications, such as hypertension, suspected multiple pregnancy, previous caesarean section, suspected still birth, ante-partum hemorrhage, and previous complication in the third trimester

- Gender: FEMALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Secondary prevention (Type: EXPERIMENTAL): Single sublingual dose of 800mcg (4 tablets) misoprostol administered to women with 350-500mL postpartum blood loss as estimated using a blood absorption mat or due to deteriorating postpartum condition of the woman as determined by provider's clinical judgment
- Universal prophylaxis (Type: ACTIVE_COMPARATOR): Single oral prophylactic dose of 600mcg (3 tablets) misoprostol administered to all women within 1 minute of deliver of baby

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Community Walking Trials: Comparing Prosthetic Feet

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DEVICE_FEASIBILITY
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Unilateral below knee amputation, use a prosthetic foot for at least 1 year~* Ability to walk 400 meters on level ground without using a walking aid and without an increase in pain~* Ability to read, write, and comprehend English~Exclusion Criteria:~* Residual skin breakdown~* Weight over 300 lbs

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Lower extremity amputees (Type: OTHER): Community walking trial comparing usual prosthetic foot with investigational prosthetic foot.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Low-dose Darunavir in a Switch Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Participant is aged ≥18 years~* Participant weight \>40kg~* Participant is on a LPV/r-containing regimen for at least 6 months with no history of other protease inhibitors~* Participant has a plasma HIV-1 RNA level \<50 copies/mL in the last 60 days~* Participant is informed and has the ability to comprehend the full nature and purpose of the study, and give voluntary written informed consent before inclusion in the study~Exclusion Criteria:~* Participants who are taking any antiretrovirals other than nucleoside/nucleotide reverse transcriptase inhibitors and LPV/r~* Any prior history of genotype-documented protease inhibitor resistance~* Participants who are taking rifampicin or any other therapy with major cytochrome P450 interactions, within the last month~* Participants who are allergic to sulphonamides~* Participants who have a current history of drug or alcohol abuse that, in the opinion of the investigator, may be an impediment to participant adherence to the protocol~* Female participants who are currently pregnant or breastfeeding~* Female participants desiring pregnancy during the next year~* Participants who have a strong likelihood of relocating far enough to make access to the study site difficult~* Any condition(s) or laboratory report that, in the opinion of the investigator, might put the participant at risk, or interfere with the study objectives or the participant's adherence to study requirements

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 100 Years
- Healthy Volunteers: t

Study Arms:
- Darunavir (Type: ACTIVE_COMPARATOR): Darunavir/Ritonavir 400/100mg once daily
- Lopinavir (Type: ACTIVE_COMPARATOR): Lopinavir/Ritonavir 400/100mg twice daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Automated Assessment of PVI Using a Novel EP Recording System

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Eligible subjects will meet all of the following inclusion criteria:~1. Subjects undergoing first-time pulmonary vein isolation indicated by investigator for the treatment of atrial fibrillation~2. Male or non-pregnant female aged ≥21 years.~3. Able and willing to provide written informed consent prior to any clinical investigation related procedure~Eligible subjects will not meet any of the following exclusion criteria:~1. Pregnant or nursing subjects.~2. Current participation in another investigational drug or device study that interferes with this Study.~3. Subjects who, in the opinion of the investigator, are not candidates for this Study.~4. Patients who have had a prior ablation procedure~5. Presence of other anatomic or comorbid conditions, or other medical, social, or psychological conditions that, in the investigator's opinion, could limit the subject's ability to participate in the clinical investigation or to comply with follow-up requirements, or impact the scientific soundness of the clinical investigation results.~6. Life expectancy less than 12 month~7. Subjects who, in the opinion of the investigator, are considered part of any vulnerable population.

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Single Group (Type: EXPERIMENTAL): Index EP Procedure: Ablation of atrial fibrillation

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Alkalinized Lidocaine in the Endotracheal Tube Cuff on the Incidence of Coughing During Emergence

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients undergoing elective short-duration surgery under general anesthesia (expected duration of less than 2 hours)~* Physical status 1-3~Exclusion Criteria:~* Asthma or severe pulmonary disease~* Pulmonary tract infection~* Anticipated difficult intubation~* Current use of cough medicine~* Contraindication to lidocaine~* Pregnancy~* Airway surgery~* Inability to provide informed consent~* Patient refusal

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Alkalinized lidocaine (Type: ACTIVE_COMPARATOR): The endotracheal tube cuff will be pre-filled at least 90 minutes before intubation with alkalinized lidocaine. Endotracheal tube cuff will be emptied before intubation and then re-filled with the same mixture following intubation to secure the position of the endotracheal tube. (cuff will be inflated until there is no air leak around the tube).~During emergence, when the expired fraction of desflurane reaches 0.2 MAC, the patient will be asked to open his eyes every 30 seconds. Any coughing effort before 0.2 MAC will be considered as a treatment failure and the patient will be treated according to the attending anaesthesiologist.
- Saline (Type: PLACEBO_COMPARATOR): The endotracheal tube cuff will be pre-filled at least 90 minutes before intubation with saline. Endotracheal tube cuff will be emptied before intubation and then re-filled with the same mixture following intubation to secure the position of the endotracheal tube. (cuff will be inflated until there is no air leak around the tube).~During emergence, when the expired fraction of desflurane reaches 0.2 MAC, the patient will be asked to open his eyes every 30 seconds. Any coughing effort before 0.2 MAC will be considered as a treatment failure and the patient will be treated according to the attending anaesthesiologist.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Timing Progesterone Luteal Support on Embryo Transfer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* first ICSI trial, normal uterus, normal cervix, normal ovarian response ,easy mock transfer,patient consenting~Exclusion Criteria:~* age over 38, difficult mock transfer, low and high ovarian response, patient not consenting

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 38 Years
- Healthy Volunteers: f

Study Arms:
- Egg retrieval arm (Type: EXPERIMENTAL): 67 ICSI cases are started daily 100 mg IM prontogest on the day of egg retrieval until the day of pregnancy test.
- Embryo transfer arm (Type: ACTIVE_COMPARATOR): 66 ICSI cases are started daily 100 mg IM prontogest on the day of embryo transfer until the day of pregnancy test.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Intradialytic Parenteral Nutrition in Hemodialysis Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* hemodialysis therapy more than 6 months~* three times per week hemodialysis~* albumin \< 35 g/l~* prealbumin \< 250 mg/l~* phase angle \< 4,5°~* SGA score grade B or C~* informed consent~Exclusion Criteria:~* inadequate dialysis (Kt/V \< 1,2)~* chemotherapy or radiotherapy~* cardiac pacemaker~* acute bacterial infection~* acute immunological disease~* cancer disease~* severe hepatic insufficiency~* interferon therapy~* HIV disease~* severe diabetes mellitus

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Intradialytic parenteral nutrition (Type: EXPERIMENTAL): Individually compounded intradialytic parenteral nutrition (IDPN) including glucose, amino acids, lipids, L-Carnitine, trace elements and water-soluable vitamins 3x / week over 16 weeks + 12 weeks postinterventional observation.
- Control Group (Type: NO_INTERVENTION): Observation over 28 weeks (16 + 12 weeks).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete